Item 8.01 Other Events.

On January 10, 2023, Vistagen Therapeutics, Inc. (the "Company") announced that the last patient in the Company's exploratory Phase 2 clinical trial of PH94B for the treatment of adults experiencing adjustment disorder with anxiety ("AjDA") has completed the study protocol. The exploratory Phase 2 clinical trial is a U.S. multi-center, randomized, double-blind, placebo-controlled study intended to evaluate efficacy, safety and tolerability of PH94B administered four times per day over four weeks for the treatment of adjustment disorder with anxiety symptoms in adults. A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits Index



Exhibit No.              Description
   99.1       Press Release issued by Vistagen
              Therapeutics, Inc., dated January
              10, 2023.
    104       Cover Page Interactive Data File
              (embedded within the Inline XBRL
              document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses